Emergent BioSolutions, Inc. is a pharmaceutical company based in the United States of America. The company has a medium risk ESG score of 21.7. Emergent BioSolutions offers public health products to government and healthcare providers through its three segments - Commercial, Products, and Services. The commercial segment, including NARCAN® and other products, generates the key revenue.